Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Medscape

Drop in HIV/HCV Coinfections After Nationwide HCV Program

“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...
Nasdaq

Atea Pharmaceuticals Advances HCV Treatment with Ongoing Phase 3 C-BEYOND Trial and Promising Phase 2 Results for Bemnifosbuvir and Ruzasvir at EASL 2025

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...
Healio

Measurements for HCV cure could be done earlier among people who inject drugs

Please provide your email address to receive an email when new articles are posted on . Measurements taken for HCV cure at 4 weeks produced identical results for people who inject drugs as those taken ...
Seeking Alpha

Atea anticipates top line Phase III HCV results midyear 2026 while advancing HEV program

Jean-Pierre Sommadossi, Founder, Chairman, CEO & President, reported substantial clinical progress, highlighting advancement in the global Phase III program evaluating bemnifosbuvir and ruzasvir for ...

US overlooks drug treatment centers in hepatitis C fight

MANCHESTER and LONDON, England — Alison Starkie spends her days tracking down people who need testing or treatment for hepatitis C, especially those who are unhoused or actively using drugs. Starkie, ...